Analyst Price Target is $3.25
▲ +39.48% Upside Potential
This price target is based on 0 analysts offering 12 month price targets for Theratechnologies in the last 3 months. The average price target is $3.25, with a high forecast of $3.25 and a low forecast of $3.25. The average price target represents a 39.48% upside from the last price of $2.33.
Current Consensus is
The current consensus among 0 investment analysts is to n/a stock in Theratechnologies. This rating has held steady since January 2022, when it changed from a Hold consensus rating.
Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA and EGRIFTA SV, for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo, an injection refers to ibalizumab for the treatment of multidrug resistant HIV-1 infected patients. Its pipeline products include F8 Formulation for the treatment of lipodystrophy in people living with HIV; TH1902, which is in Phase 1/Part A clinical trials for the treatment of triple negative breast cancer; and TH1904 for the treatment of ovarian cancer. The company was incorporated in 1993 and is headquartered in Montreal, Canada.